I hereby certify that this correspondence is being re with the United States Postal Service with Suffice

> Jodie M. Riv (Printed Name)

> > (Signature)

August 1, 2002 (Date of Deposit)

postage as First Class Mail in an enven Commissioner for Patents, Washington

the date below.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

DAHLEN et al.

Title:

USE OF B-TYPE NATRIURETIC PEPTIDE AS A PROGNOSTIC INDICATOR IN **ACUTE CORONARY SYNDROMES**

Appl. No.:

09/835.298

Filing Date:

April 13, 2001

3. 数据 1. 人类 1. 文章

1 2 for 10 1 3 8 1 2 5 1 5 1 1 1 1

Examiner:

G. Gabel

GAU:.

1641

TRANSMITTAL

COPY OF PAPERS ORIGINALLY FILED

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

Transmitted herewith is:

 \boxtimes Response to Restriction requirement.

 \boxtimes The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872 (Order No. 071949-5301). Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872 (Order No. 071949-5301).

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

P.O. Box 80278

San Diego, CA 92138-0278 Telephone: (858) 847-6721

Facsimile:

(858) 792-6773

Michael A. Whittaker

Attorney for Applicant

Registration No. 46,230



COPY OF PAPERS ORIGINALLY FILED

Docket No.: 071949-5301

Patent 8/19/02 Patent 8/19/02 Se ≥ III

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dahlen et al.

Serial No.: 09/835,298

Filed: April 13, 2001

Title: Use of B-type Natriuretic Peptide as a Prognostic Indicator in Acute Coronary

Syndromes

Examiner: Gailene Gabel

Art Unit: 1641

United States Postal Service's "Firs Addressee" service under 37 C.F.R. below and is addressed to: Commissioner for Patents	
Box NO-FEE	_
Washington. D.C. 20231-0001	
((Date of De	eposit)
Jodie M. R	
(Printed Na	ime)
alacci	LA .
(Signatur	e)

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, D.C. 20231 Box Non-Fee Amendment

Dear Sir:

In response to the Office Action mailed July 3, 2002 ("Paper No. 5"), please enter the following amendments and consider the following remarks.

IN THE CLAIMS

Please cancel claims 10 and 20-21 without prejudice to their future prosecution. Please enter the following new claim:

22. (New) A method of determining a prognosis of a patient diagnosed with a non-ST-elevation acute coronary syndrome, the method comprising:

determining a level of a polypeptide originating from pre-pro B-type natriuretic peptide in a sample obtained from said patient; and

correlating said polypeptide level to said patient prognosis by determining if said polypeptide level is associated with a predisposition to an adverse outcome of said non-ST-

(b)